Equities

Oncimmune Holdings PLC

ONC:LSE

Oncimmune Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)24.10
  • Today's Change0.50 / 2.12%
  • Shares traded14.87k
  • 1 Year change-40.49%
  • Beta0.7105
Data delayed at least 20 minutes, as of May 01 2024 16:09 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Oncimmune Holdings PLC had revenues fall -50.26% from 2.32m to 1.15m, though the company grew net income from a loss of 11.39m to a gain of 4.10m.
Gross margin68.75%
Net profit margin-533.94%
Operating margin-340.63%
Return on assets-66.15%
Return on equity--
Return on investment-131.46%
More ▼

Cash flow in GBPView more

In 2023, Oncimmune Holdings PLC increased its cash reserves by 125.19%, or 1.78m. Cash Flow from Investing totalled 11.58m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 6.79m for operations while cash used for financing totalled 3.02m.
Cash flow per share-0.0713
Price/Cash flow per share--
Book value per share0.0089
Tangible book value per share-0.0189
More ▼

Balance sheet in GBPView more

Oncimmune Holdings PLC has a Debt to Total Capital ratio of 88.97%.
Current ratio3.91
Quick ratio3.75
Total debt/total equity8.07
Total debt/total capital0.8897
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.